GlassScriptPhysician profile
Ayesha Parvez
NPI 1710107339
$8,621.48
in general payments reported to CMS, 2019-2025
48 companies · $1,787 in 2025
The $1,787 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $817 · 2020: $816 · 2021: $865 · 2022: $877 · 2023: $1,782 · 2024: $1,678 · 2025: $1,787.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,247.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,246.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $1,347.75 | 2019-2024 | |
| Novo Nordisk INC | $929.62 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $879.89 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Dexcom, INC. | $523.33 | 2019-2025 | Dexcom G6 Transmitter |
| Amgen INC. | $402.59 | 2020-2025 | Evenity, Prolia, Prolia |
| Corcept Therapeutics | $399.94 | 2019-2025 | Korlym |
| Intuity Medical INC | $395.13 | 2023 | Pogo Automatic Blood Glucose Monitoring System |
| Antares Pharma, INC. | $389.18 | 2019-2025 | Xyosted, Nocdurna, Tlando |
| Abbott Laboratories | $363.59 | 2019-2025 | Freestyle Libre 3, Proclaim |
| Boehringer Ingelheim Pharmaceuticals, INC. | $319.68 | 2020-2025 | Jardiance, Synjardy |
| Mannkind Corporation | $278.24 | 2019-2025 | Afrezza |
| Tolmar, INC. | $211.98 | 2023-2025 | Jatenzo |
| Xeris Pharmaceuticals, INC. | $194.87 | 2020-2025 | Recorlev, Gvoke Hypopen |
| Insulet Corporation | $174.80 | 2019-2025 | Omnipod |
| Merck Sharp & Dohme LLC | $173.11 | 2019-2021 |
Show all 48 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $165.41 | 2019-2023 | Farxiga |
| Medtronic, INC. | $126.39 | 2021-2024 | Minimed 780g |
| Ibsa Pharma INC. | $124.82 | 2020-2025 | Tirosint, Licart, Tirosint |
| Cequr Corporation | $98.96 | 2021-2023 | Cequr Simplicity |
| Tandem Diabetes Care, INC. | $89.42 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Ascendis Pharma Endocrinology INC | $85.59 | 2023-2025 | Yorvipath |
| Novartis Pharmaceuticals Corporation | $78.73 | 2024-2025 | |
| Beta Bionics, INC. | $78.27 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Ascensia Diabetes Care US INC. | $63.71 | 2025 | |
| Astellas Pharma US INC | $60.54 | 2025 | Veozah |
| Ipsen Biopharmaceuticals, INC | $59.72 | 2019-2021 | |
| Recordati_rare_diseases_inc. | $54.86 | 2025 | Isturisa |
| Sequel Med Tech, LLC | $50.63 | 2025 | Twiist |
| Abbvie INC. | $49.34 | 2021-2025 | |
| Amneal Pharmaceuticals LLC | $47.68 | 2019-2025 | Unithroid |
| Rhythm Pharmaceuticals, INC. | $40.91 | 2025 | Imcivree |
| Bayer Healthcare Pharmaceuticals INC. | $38.10 | 2021-2022 | |
| Halozyme INC | $33.83 | 2023 | |
| Soleno Therapeutics, INC. | $33.10 | 2025 | Vykat Xr |
| Medtronic Minimed, INC. | $27.55 | 2019 | |
| Therapeuticsmd, INC. | $24.82 | 2019 | |
| Chiasma, INC. | $21.33 | 2021 | |
| Kyowa Kirin, INC. | $20.00 | 2024 | Crysvita |
| Sandoz INC. | $19.67 | 2025 | Hyrimoz |
| Madrigal Pharmaceuticals | $18.54 | 2025 | Rezdiffra |
| Amryt Pharma Holdings LTD | $18.53 | 2023 | Mycapssa |
| Acella Pharmaceuticals, LLC | $18.10 | 2025 | NP Thyroid 60 |
| Alexion Pharmaceuticals, INC. | $18.03 | 2023 | Strensiq |
| Clarus Therapeutics INC. | $17.86 | 2021 | |
| Becton, Dickinson and Company | $13.74 | 2019 | |
| Gilead Sciences, INC. | $13.53 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $13.40 | 2021 | |
| Janssen Pharmaceuticals, INC | $12.67 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ayesha Parvez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.